Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02775773Phase 3Completed

Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

Role: lead

NCT02503319Phase 3Withdrawn

Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH (TRANOXY2015)

Role: lead

NCT02815852Completed

RETROSPECTIVE ANALYSIS OF BREAST BIOPSIES IN WOMEN YOUNGER THAN 40 YEARS OLD

Role: lead

NCT02604238Phase 3Withdrawn

Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism

Role: lead

All 4 trials loaded